BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Director Jean Jacques Bienaime Sells 20,000 Shares

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Director Jean Jacques Bienaime sold 20,000 shares of the company’s stock in a transaction on Friday, April 12th. The shares were sold at an average price of $91.26, for a total value of $1,825,200.00. Following the sale, the director now owns 474,994 shares of the company’s stock, valued at approximately $43,347,952.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Jean Jacques Bienaime also recently made the following trade(s):

• On Tuesday, March 5th, Jean Jacques Bienaime sold 1,000 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $85.51, for a total value of $85,510.00.
• On Tuesday, February 27th, Jean Jacques Bienaime sold 1,000 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $90.35, for a total value of $90,350.00.
• On Friday, February 9th, Jean Jacques Bienaime sold 15,000 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $88.28, for a total value of $1,324,200.00.

BioMarin Pharmaceutical Price Performance

Shares of BioMarin Pharmaceutical stock opened at $91.51 on Tuesday. The stock has a 50 day moving average of $87.53 and a 200 day moving average of $89.08. BioMarin Pharmaceutical Inc. has a 12 month low of $76.02 and a 12 month high of $100.38. The firm has a market cap of $17.27 billion, a PE ratio of 103.99, a PEG ratio of 1.76 and a beta of 0.31. The company has a current ratio of 2.51, a quick ratio of 1.57 and a debt-to-equity ratio of 0.12.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its quarterly earnings data on Thursday, February 22nd. The biotechnology company reported $0.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.44 by $0.05. BioMarin Pharmaceutical had a return on equity of 5.01% and a net margin of 6.93%. The business had revenue of $646.21 million for the quarter, compared to the consensus estimate of $639.53 million. During the same period in the prior year, the business posted $0.11 earnings per share. The company’s quarterly revenue was up 20.2% compared to the same quarter last year. On average, research analysts expect that BioMarin Pharmaceutical Inc. will post 1.93 EPS for the current fiscal year.

Institutional Investors Weigh In On BioMarin Pharmaceutical

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Stratos Wealth Partners LTD. raised its position in BioMarin Pharmaceutical by 2.1% during the fourth quarter. Stratos Wealth Partners LTD. now owns 5,709 shares of the biotechnology company’s stock valued at $550,000 after purchasing an additional 115 shares during the period. CWM LLC raised its position in BioMarin Pharmaceutical by 10.0% during the third quarter. CWM LLC now owns 1,301 shares of the biotechnology company’s stock valued at $115,000 after purchasing an additional 118 shares during the period. KB Financial Partners LLC raised its position in BioMarin Pharmaceutical by 51.3% during the third quarter. KB Financial Partners LLC now owns 348 shares of the biotechnology company’s stock valued at $31,000 after purchasing an additional 118 shares during the period. Virtus ETF Advisers LLC raised its position in BioMarin Pharmaceutical by 3.8% during the fourth quarter. Virtus ETF Advisers LLC now owns 3,342 shares of the biotechnology company’s stock valued at $322,000 after purchasing an additional 121 shares during the period. Finally, Howe & Rusling Inc. raised its holdings in shares of BioMarin Pharmaceutical by 0.4% in the fourth quarter. Howe & Rusling Inc. now owns 36,279 shares of the biotechnology company’s stock worth $3,755,000 after buying an additional 128 shares during the period. 98.71% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts recently commented on the company. Cantor Fitzgerald reiterated an “overweight” rating and set a $100.00 price objective on shares of BioMarin Pharmaceutical in a research report on Friday, February 23rd. Stifel Nicolaus reissued a “buy” rating and set a $101.00 price target on shares of BioMarin Pharmaceutical in a report on Thursday, December 21st. Robert W. Baird cut their price target on BioMarin Pharmaceutical from $127.00 to $104.00 and set an “outperform” rating for the company in a report on Tuesday, January 30th. Canaccord Genuity Group reissued a “hold” rating and set a $91.00 price target on shares of BioMarin Pharmaceutical in a report on Thursday, February 29th. Finally, Piper Sandler cut their price target on BioMarin Pharmaceutical from $115.00 to $107.00 and set an “overweight” rating for the company in a report on Friday, February 23rd. Seven analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, BioMarin Pharmaceutical presently has a consensus rating of “Moderate Buy” and a consensus price target of $107.61.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.